Delivery Order SPE2DR25D1100-SPE2DR26FCV4A
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on December 2, 2025, for the supply of Restasis 0.05% eye emulsion in 60-unit quantities, with a ceiling value of $5,081.08 and an ultimate completion date of December 3, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's...
- The Defense Logistics Agency has awarded AmerisourceBergen Drug Corp a $10,783.83 firm fixed-price delivery order for Restasis 0.05% Eye Emulsion (60 units), with an ultimate completion date of December 5, 2025. This is a competitively awarded, non-set-aside contract with performance taking place at the awardee's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract action under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Restasis 0.05% eye emulsion in a 30-count package on April 24, 2025, with a ceiling value of $1,221.73 and a completion date of April 25, 2025. This delivery order represents a firm fixed-price, non-set-aside contract executed as a child order under AmerisourceBergen's larger pharmaceutical supply agreement with DLA. The vendor, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $1,541.08 for Restasis 0.05% Eye Emulsion (30-count units) on May 6, 2025, with an ultimate completion date of May 7, 2025. This firm fixed-price delivery order represents a non-competitive procurement under a larger indefinite delivery contract vehicle. The product will be delivered to the place of performance in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters....
- The Defense Logistics Agency awarded a delivery order valued at $14,980.58 to AmerisourceBergen Drug Corp for the supply of Restasis 0.05% Eye Emulsion (60-count units) on September 4, 2025, with an ultimate completion date of September 5, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and represents a continuation of the vendor's extensive pharmaceutical supply relationship with the federal government. The product will be delivered to...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 7, 2025, for the supply of Restasis 0.05% Eye Emulsion in 30-count units, with a contract ceiling value of $2,707.19 and an ultimate completion date of November 10, 2025. This firm fixed-price delivery order represents a non-competitive set-aside contract and is being performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The award is issued under AmerisourceBergen's...
- The Defense Logistics Agency awarded a $23,799.46 delivery order to AmerisourceBergen Drug Corp for Restasis 0.05% Eye Emulsion (60 count) on May 8, 2025, with completion scheduled for May 9, 2025. This firm fixed-price contract, which was competitively awarded with no set-aside designation, will be performed at the contractor's corporate office in Conshohocken, Pennsylvania. Restasis is a prescription ophthalmic medication used to treat dry eye disease, representing part of...
- The Defense Logistics Agency awarded a delivery order valued at $18,550.26 to AmerisourceBergen Drug Corp for RESTASIS 0.05% Eye Emulsion (60 count) on September 11, 2025, with an ultimate completion date of September 12, 2025. This firm fixed price delivery order was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a child delivery order under AmerisourceBergen's...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for $1,117.68 on September 26, 2025, for RESTASIS 0.05% Eye Emulsion (60 count units). This is a firm fixed price, competitively awarded contract with no set-aside designation and an ultimate completion date of September 29, 2025. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a $2,169.08 delivery order to AmerisourceBergen Drug Corp for Restasis 0.05% Eye Emulsion (30-count units) on June 2, 2025, with an ultimate completion date of June 3, 2025. This is a firm fixed price, non-set-aside contract with performance at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical...
- SPE2DR25D1100Indefinite Delivery Contract
- SPE2DR25D1100-SPE2DR26FCV4ADelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $4,871.29 to AmerisourceBergen Drug Corp for the supply of Restasis 0.05% Eye Emulsion (30-count units) on December 17, 2025, with an ultimate completion date of December 18, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999,999,999.00 and extends through December 2026, serving as a comprehensive global pharmaceutical support vehicle for military healthcare programs. As a major pharmaceutical distributor and critical federal medical procurement vendor, AmerisourceBergen supplies a broad range of pharmaceutical products and medical supplies to support Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. The company's extensive portfolio of DLA contract awards demonstrates its capability to fulfill diverse medical supply requirements across multiple therapeutic domains, from specialty medications and vaccines to medical devices and diagnostic test kits. This particular delivery order for Restasis, an ophthalmic emulsion used in the treatment of dry eye disease, represents a routine procurement supporting military and veteran healthcare needs through the established prime vendor framework.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.9k | 12/16/25 |